Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
RIOMET ER™
(metformin hydrochloride for extended-release) Oral Suspension
WARNING
LACTIC ACIDOSIS
Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. The onset of metforminassociated lactic acidosis is often subtle, accompanied only by nonspecific symptoms such as malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Metforminassociated lactic acidosis was characterized by elevated blood lactate levels (>5 mmol/Liter), anion gap acidosis (without evidence of ketonuria or ketonemia), an increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL [see WARNINGS AND PRECAUTIONS].
Risk factors for metformin-associated lactic acidosis include renal impairment, concomitant use of certain drugs (e.g. carbonic anhydrase inhibitors such as topiramate), age 65 years old or greater, having a radiological study with contrast, surgery and other procedures, hypoxic states (e.g., acute congestive heart failure), excessive alcohol intake, and hepatic impairment.
Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided [see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS].
If metformin-associated lactic acidosis is suspected, immediately discontinue RIOMET ER and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended [see WARNINGS AND PRECAUTIONS].
RIOMET ER (metformin hydrochloride for extended-release oral suspension) is a biguanide. The chemical name of metformin hydrochloride is N,N-dimethylimidodicarbonimidic diamide hydrochloride. The structural formula is as shown below:
 |
Metformin hydrochloride, USP is a white crystalline powder with a molecular formula of C4H11N5•HCl and a molecular weight of 165.62. It is freely soluble in water, slightly soluble in alcohol; practically insoluble in acetone and in methylene chloride. The pKa of metformin is 12.4.
The pH of a 1% aqueous solution of metformin hydrochloride, USP is 6.37 to 6.53.
RIOMET ER is available as follows:
The oral suspension include the following inactive ingredients: carboxymethyl cellulose sodium, colloidal silicon dioxide, dibutyl sebacate, ethyl cellulose, hypromellose, magnesium stearate, methyl paraben, microcrystalline cellulose, propyl paraben, sucralose, strawberry flavor Type FL # 28082 (flavoring ingredients, propylene glycol and glycerin) xanthan gum and xylitol.
RIOMET ER is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Discontinue RIOMET ER at the time of, or prior to, an iodinated contrast imaging procedure in patients with an eGFR between 30 and 60 mL/min/1.73 m²; in patients with a history of liver disease, alcoholism, or heart failure; or in patients who will be administered intra-arterial iodinated contrast. Re-evaluate eGFR 48 hours after the imaging procedure; restart RIOMET ER if renal function is stable.
RIOMET ER is supplied as a powder for oral suspension which must be reconstituted with the accompanying diluent prior to dispensing. Both the powder and diluent contain metformin HCl.
Please read these instructions completely before you begin.
Step-A Remove the bottle containing Drug Pellets and Drug Diluent Bottle along with measuring cup from the box. Do not use if: The expiration date has passed. The bottle appears damaged or defective.
Step-B Remove the child-resistant cap (push down and turn) from the bottle containing Drug Pellets and Drug Diluent Bottle, and retain.
Step-C Pour the contents of bottle containing Drug Pellets in to the Drug Diluent bottle and discard the empty Pellet bottle (See Figure 1).
Figure 1
 |
Step-D Close the Drug Diluent bottle with child resistant cap.
Step-E Shake the Drug Diluent bottle continuously in an up and down direction for at least 2 full minutes. This is important for the product to mix evenly. The reconstituted suspension is 500 mg/5 mL.
Figure 2
 |
Store reconstituted suspension in the original bottle between 20°C to 25°C (68°F to 77°F). Do not repackage.
For extended-release oral suspension: 47.31 grams of metformin HCl as white to off-white pellets and white to off-white diluent for reconstitution in 473 mL bottle pack
The reconstituted suspension is 500 mg/5 mL appearing as white to off-white suspension containing white to off-white pellets
RIOMET ER (metformin hydrochloride for extended-release oral suspension): 47.31 grams of metformin HCl as white to off-white pellets and white to off-white diluent for reconstitution in 473 mL bottle pack
The reconstituted suspension is 500 mg/5 mL appearing as white to off-white suspension containing white to off-white pellets. It is supplied as followings:
| Package Configuration | NDC | Description | Supplied as |
| 16 oz (473 mL) Round Bottle Pack | 10631-019-17 | White to off-white pellets containing 37.85 g of metformin HCl in drug pellets bottle and white to off-white dispersion containing 9.46 g of metformin HCl in drug diluent bottle intended for reconstitution. | Carton contains 1 bottle of drug pellets, 1 bottle of diluent, and one dosing cup. |
Store between 20°C to 25°C (68°F to 77°F) in the original bottle. Do not repackage.
Excursions permitted between 15°C and 30°C (59°F and 86°F). [See USP Controlled Room Temperature.]
The shelf-life of the constituted oral suspension is 100 days. Any unused portion of the reconstituted suspension must be discarded after 100 days.
Manufactured by: Sun Pharmaceutical Industries Limited, MOHALI, INDIA. Distributed by: Sun Pharmaceutical Industries, Inc., Cranbury, NJ 08512. Revised: Aug 2019
The following adverse reactions are also discussed elsewhere in the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
In a U.S. clinical trial of metformin immediate-release tablet in patients with type 2 diabetes mellitus, a total of 141 patients received metformin immediate-release tablet up to 2,550 mg per day. Adverse reactions reported in greater than 5% of metformin immediate-release tablet treated patients and that were more common than in placebo-treated patients, are listed in Table 1.
Table 1: Adverse Reactions from a Clinical Trial of
Metformin Occurring >5% and More Common than Placebo in Patients with Type 2
Diabetes Mellitus
| Metformin Immediate-Release Tablet (n = 141) |
Placebo (n = 145) |
|
| Diarrhea | 53% | 12% |
| Nausea/Vomiting | 26% | 8% |
| Flatulence | 12% | 6% |
| Asthenia | 9% | 6% |
| Indigestion | 7% | 4% |
| Abdominal Discomfort | 6% | 5% |
| Headache | 6% | 5% |
Diarrhea led to discontinuation of metformin immediate-release tablet in 6% of patients. Additionally, the following adverse reactions were reported in ≥ 1% to ≤ 5% of metformin immediaterelease tablet treated patients and were more commonly reported with metformin immediate-release tablet than placebo: abnormal stools, hypoglycemia, myalgia, lightheaded, dyspnea, nail disorder, rash, sweating increased, taste disorder, chest discomfort, chills, flu syndrome, flushing, palpitation.
In metformin immediate-release tablet clinical trials of 29 week duration, a decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients.
In clinical trials with metformin in pediatric patients with type 2 diabetes mellitus, the profile of adverse reactions was similar to that observed in adults.
In placebo-controlled trials, 781 patients were administered metformin extended-release tablet. Adverse reactions reported in greater than 5% of the metformin extended-release tablet patients, and that were more common in metformin extended-release tablet- than placebo-treated patients, are listed in Table 2.
Table 2: Adverse Reactions from Clinical Trials of
Metformin Hydrochloride Extended- Release Tablet Occurring >5% and More
Common than Placebo in Patients with Type 2 Diabetes Mellitus
| Adverse Reaction | Metformin Hydrochloride Extended- Release Tablet (n = 781) |
Placebo (n = 195) |
| Diarrhea | 10% | 3% |
| Nausea/Vomiting | 7% | 2% |
| *Reactions that were more common in metformin hydrochloride extended-release tablet- than placebo-treated patients. | ||
Diarrhea led to discontinuation of metformin hydrochloride extended-release tablet in 0.6% of patients. Additionally, the following adverse reactions were reported in ≥ 1.0% to ≤ 5.0% of metformin hydrochloride extended-release tablet patients and were more commonly reported with metformin hydrochloride extended-release tablet than placebo: abdominal pain, constipation, distention abdomen, dyspepsia/heartburn, flatulence, dizziness, headache, upper respiratory infection, taste disturbance.
The following adverse reactions have been identified during post approval use of metformin. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Cholestatic, hepatocellular, and mixed hepatocellular liver injury have been reported with postmarketing use of metformin.
Table 3 presents clinically significant drug interactions with RIOMET ER.
Table 3: Clinically Significant Drug Interactions with
RIOMET ER
| Carbonic Anhydrase Inhibitors | |
| Clinical Impact: | Carbonic anhydrase inhibitors frequently cause a decrease in serum bicarbonate and induce non-anion gap, hyperchloremic metabolic acidosis. Concomitant use of these drugs with RIOMET ER may increase the risk for lactic acidosis. |
| Intervention: | Consider more frequent monitoring of these patients. |
| Examples: | Topiramate, zonisamide, acetazolamide or dichlorphenamide. |
| Drugs that Reduce Metformin Clearance | |
| Clinical Impact: | Concomitant use of drugs that interfere with common renal tubular transport systems involved in the renal elimination of metformin (e.g., organic cationic transporter-2 [OCT2] / multidrug and toxin extrusion [MATE] inhibitors) could increase systemic exposure to metformin and may increase the risk for lactic acidosis [see CLINICAL PHARMACOLOGY]. |
| Intervention: | Consider the benefits and risks of concomitant use with RIOMET ER. |
| Examples: | Ranolazine, vandetanib, dolutegravir, and cimetidine. |
| Alcohol and Medications Containing Alcohol | |
| Clinical Impact: | Alcohol is known to potentiate the effect of metformin on lactate metabolism. Further, consuming alcohol or oral liquid medications containing alcohol (e.g. cough/cold or pain medications) concomitantly with RIOMET ER can accelerate the release and absorption of metformin [see CLINICAL PHARMACOLOGY]. |
| Intervention: | Warn patients against excessive alcohol intake while receiving RIOMET ER and not to consume alcohol or medications containing alcohol concurrently with RIOMET ER. |
| Insulin Secretagogues or Insulin | |
| Clinical Impact: | Coadministration of RIOMET ER with an insulin secretagogue (e.g., sulfonylurea) or insulin may increase the risk of hypoglycemia. |
| Intervention: | Patients receiving an insulin secretagogue or insulin may require lower doses of the insulin secretagogue or insulin. |
| Drugs Affecting Glycemic Control | |
| Clinical Impact: | Certain drugs tend to produce hyperglycemia and may lead to loss of glycemic control. |
| Intervention: | When such drugs are administered to a patient receiving RIOMET ER, observe the patient closely for loss of blood glucose control. When such drugs are withdrawn from a patient receiving RIOMET ER, observe the patient closely for hypoglycemia. |
| Examples: | Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. |
Included as part of the PRECAUTIONS section.
There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases. These cases had a subtle onset and were accompanied by nonspecific symptoms such as malaise, myalgias, abdominal pain, respiratory distress, or increased somnolence; however, hypotension and resistant bradyarrhythmias have occurred with severe acidosis. Metforminassociated lactic acidosis was characterized by elevated blood lactate concentrations (> 5 mmol/L), anion gap acidosis (without evidence of ketonuria or ketonemia), and an increased lactate: pyruvate ratio; metformin plasma levels were generally > 5 mcg/mL. Metformin decreases liver uptake of lactate increasing lactate blood levels which may increase the risk of lactic acidosis, especially in patients at risk.
If metformin-associated lactic acidosis is suspected, general supportive measures should be instituted promptly in a hospital setting, along with immediate discontinuation of RIOMET ER. In RIOMET ER treated patients with a diagnosis or strong suspicion of lactic acidosis, prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin (metformin hydrochloride is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions).
Hemodialysis has often resulted in reversal of symptoms and recovery.
Educate patients and their families about the symptoms of lactic acidosis and, if these symptoms occur, instruct them to discontinue RIOMET ER and report these symptoms to their healthcare provider.
For each of the known and possible risk factors for metformin-associated lactic acidosis, recommendations to reduce the risk of and manage metformin-associated lactic acidosis are provided below:
The risk of metformin accumulation and metformin-associated lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney. Clinical recommendations based upon the patient’s renal function include [see DOSAGE AND ADMINISTRATION, CLINICAL PHARMACOLOGY]:
In clinical trials of 29 week duration with metformin HCl tablets, a decrease to subnormal levels of previously normal serum vitamin B12 levels was observed in approximately 7% of patients. Such decrease, possibly due to interference with B12 absorption from the B12-intrinsic factor complex, may be associated with anemia but appears to be rapidly reversible with discontinuation of metformin or vitamin B12 supplementation. Certain individuals (those with inadequate vitamin B12 or calcium intake or absorption) appear to be predisposed to developing subnormal vitamin B12 levels. Measure hematologic parameters on an annual basis and vitamin B12 at 2 to 3 year intervals in patients on RIOMET ER and manage any abnormalities [see ADVERSE REACTIONS].
Insulin and insulin secretagogues (e.g., sulfonylurea) are known to cause hypoglycemia. RIOMET ER may increase the risk of hypoglycemia when combined with insulin and/or an insulin secretagogue. Therefore, a lower dose of insulin or insulin secretagogue may be required to minimize the risk of hypoglycemia when used in combination with RIOMET ER [see DRUG INTERACTIONS].
Advise the patient to read the FDA-approved patient labeling (PATIENT INFORMATION and Instructions for Use).
Instruct patients or caregivers to use the supplied dosing cup to measure the prescribed amount of medication.
Explain the risks of lactic acidosis, its symptoms, and conditions that predispose to its development. Advise patients to discontinue RIOMET ER immediately and to promptly notify their healthcare provider if unexplained hyperventilation, myalgias, malaise, unusual somnolence or other nonspecific symptoms occur. Counsel patients against excessive alcohol intake and inform patients about importance of regular testing of renal function while receiving RIOMET ER. Instruct patients to inform their doctor that they are taking RIOMET ER prior to any surgical or radiological procedure, as temporary discontinuation may be required [see WARNINGS AND PRECAUTIONS].
Inform patients that hypoglycemia may occur when RIOMET ER is coadministered with oral sulfonylureas and insulin. Explain to patients receiving concomitant therapy the risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development [see WARNINGS AND PRECAUTIONS].
Inform patients about importance of regular hematological parameters while receiving RIOMET ER [see WARNINGS AND PRECAUTIONS].
Inform females that treatment with RIOMET ER may result in ovulation in some premenopausal anovulatory women which may lead to unintended pregnancy [see Use In Specific Populations].
Long-term carcinogenicity studies have been performed in rats (dosing duration of 104 weeks) and mice (dosing duration of 91 weeks) at doses up to and including 900 mg/kg/day and 1500 mg/kg/day, respectively. These doses are both approximately 3 times the maximum recommended human daily dose of 2,550 mg based on body surface area comparisons. No evidence of carcinogenicity with metformin was found in either male or female mice. Similarly, there was no tumorigenic potential observed with metformin in male rats. There was, however, an increased incidence of benign stromal uterine polyps in female rats treated with 900 mg/kg/day.
There was no evidence of a mutagenic potential of metformin in the following in vitro tests: Ames test (S. typhimurium), gene mutation test (mouse lymphoma cells), or chromosomal aberrations test (human lymphocytes). Results in the in vivo mouse micronucleus test were also negative.
Fertility of male or female rats was unaffected by metformin when administered at doses as high as 600 mg/kg/day, which is approximately 2 times the maximum recommended human daily dose of 2,550 mg based on body surface area comparisons.
Limited data with metformin in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [see Data]. There are risks to the mother and fetus associated with poorly controlled diabetes mellitus in pregnancy [see Clinical Considerations].
No adverse developmental effects were observed when metformin was administered to pregnant Sprague Dawley rats and rabbits during the period of organogenesis at doses up to 2- and 5times, respectively, a 2,550 mg clinical dose, based on body surface area [see Data].
The estimated background risk of major birth defects is 6 to 10% in women with pre-gestational diabetes mellitus with an HbA1C >7 and has been reported to be as high as 20 to 25% in women with a HbA1C >10. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Disease-Associated Maternal And/Or Embryo/Fetal Risk
Poorly-controlled diabetes mellitus in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery, and delivery complications. Poorly controlled diabetes mellitus increases the fetal risk for major birth defects, stillbirth, and macrosomia related morbidity.
Human Data
Published data from post-marketing studies have not reported a clear association with metformin and major birth defects, miscarriage, or adverse maternal or fetal outcomes when metformin was used during pregnancy. However, these studies cannot definitely establish the absence of any metforminassociated risk because of methodological limitations, including small sample size and inconsistent comparator groups.
Animal Data
Metformin hydrochloride did not adversely affect development outcomes when administered to pregnant rats and rabbits at doses up to 600 mg/kg/day. This represents an exposure of about 2 and 5 times a 2,550 mg clinical dose based on body surface area comparisons for rats and rabbits, respectively. Determination of fetal concentrations demonstrated a partial placental barrier to metformin.
Limited published studies report that metformin is present in human milk [see Data]. However, there is insufficient information to determine the effects of metformin on the breastfed infant and no available information on the effects of metformin on milk production. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for RIOMET ER and any potential adverse effects on the breastfed child from RIOMET ER or from the underlying maternal condition.
Published clinical lactation studies report that metformin is present in human milk which resulted in infant doses approximately 0.11% to 1% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 0.13 and 1. However, the studies were not designed to definitely establish the risk of use of metformin during lactation because of small sample size and limited adverse event data collected in infants.
Discuss the potential for unintended pregnancy with premenopausal women as therapy with metformin may result in ovulation in some anovulatory women.
The safety and effectiveness of RIOMET ER as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type 2 diabetes mellitus have been established. Use of RIOMET ER for this indication is supported by evidence from adequate and well- controlled studies of metformin HCl immediate-release tablet in adults with additional data from a controlled clinical study using metformin HCl immediate-release tablets in pediatric patients 10 to 16 years old with type 2 diabetes mellitus [see Clinical Studies].
Safety and effectiveness of RIOMET ER have not been established in pediatric patients less than 10 years old.
Controlled clinical studies of metformin HCl immediate-release tablet and HCl extended-release tablet did not include sufficient numbers of elderly patients to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of lactic acidosis. Assess renal function more frequently in elderly patients [see WARNINGS AND PRECAUTIONS].
Metformin is substantially excreted by the kidney, and the risk of metformin accumulation and lactic acidosis increases with the degree of renal impairment. RIOMET ER is contraindicated in severe renal impairment, patients with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² [see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, and CLINICAL PHARMACOLOGY].
Use of metformin in patients with hepatic impairment has been associated with some cases of lactic acidosis. RIOMET ER is not recommended in patients with hepatic impairment [see WARNINGS AND PRECAUTIONS].
Overdose of metformin HCl has occurred, including ingestion of amounts greater than 50 grams. Hypoglycemia was reported in approximately 10% of cases, but no causal association with metformin hydrochloride has been established. Lactic acidosis has been reported in approximately 32% of metformin overdose cases [see WARNINGS AND PRECAUTIONS]. Metformin is dialyzable with a clearance of up to 170 mL/min under good hemodynamic conditions. Therefore, hemodialysis may be useful for removal of accumulated drug from patients in whom metformin overdosage is suspected.
RIOMET ER is contraindicated in patients with:
Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion remains unchanged while fasting insulin levels and day-long plasma insulin response may decrease.
Following a single oral dose of RIOMET ER 500 mg/5 mL (dose: 750 mg) in healthy adult male subjects (N=52) when taken with high-fat meal, the mean Cmax and AUC0-t values is 815 ng/mL and 7694 ng•hr/mL, respectively (Table 4). The Tmax is achieved with a median value of 4.5 hours and a range of 3.5 to 6.5 hours.
Effect Of Food
In the same study, the administration of RIOMET ER 500 mg/5 mL following a standardized high-fat, high-calorie breakfast (containing approximately 150 kcal from protein, 250 kcal from carbohydrates and 500 kcal from fat) had minimal effect on the AUC of metformin; however, Cmax is decreased by approximately 20% when compared to dosing under fasting condition (Table 4). The median Tmax is delayed by 1 hour under fed condition compared to fasting condition.
The observed elimination half-life (t½) is similar under both fasting and fed conditions.
Table 4: Pharmacokinetic Parameters for Single 750 mg
Dose of RIOMET ER 500 mg/5 mL
| Cmax (ng/mL) Mean (±SD) | Tmax (hr)# Median (Range) | AUC0-t(ng•hr/mL) Mean (±SD) | t½(hr) Mean (±SD) | |
| Fasting condition | 1067 56 | 4.50 | 7472 02 | 4 63 |
| (N = 52) | 377.11 | (3.50 to 6.50) | 1946.10 | 1.97 |
| Fed condition | 815.39 | 5.50 | 7694.78 | 4.19 |
| (N = 52) | 180.15 | (3.50 to 10.00) | 1692.11 | 1.03 |
In vitro alcohol interaction: An in vitro dissolution study indicated an accelerated release rate of metformin from the RIOMET ER when tested with 5-40% alcohol content in the medium. The dissolution rate of metformin in the suspension increased with increasing alcohol content.
The apparent average volume of distribution (V/F) of metformin following single 750 mg oral doses of RIOMET ER is 596±173 L. Metformin is negligibly bound to plasma proteins. Metformin partitions into erythrocytes, most likely as a function of time.
Intravenous single-dose studies in normal subjects demonstrate that metformin is excreted unchanged in the urine and does not undergo hepatic metabolism (no metabolites have been identified in humans) nor biliary excretion.
Renal clearance (see Table 5) is approximately 3.5 times greater than creatinine clearance, which indicates that tubular secretion is the major route of metformin elimination. Following oral administration, approximately 90% of the absorbed drug is eliminated via the renal route within the first 24 hours, with a plasma elimination half-life of approximately 6.2 hours. In blood, the elimination half-life is approximately 17.6 hours, suggesting that the erythrocyte mass may be a compartment of distribution.
In patients with decreased renal function the plasma and blood half-life of metformin is prolonged and the renal clearance is decreased (see Table 5) [See DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS and Use In Specific Populations].
No pharmacokinetic studies of metformin have been conducted in patients with hepatic impairment [See WARNINGS AND PRECAUTIONS and Use In Specific Populations].
Limited data from controlled pharmacokinetic studies of metformin hydrochloride immediaterelease tablet in healthy elderly subjects suggest that total plasma clearance of metformin is decreased, the half-life is prolonged, and Cmax is increased, compared to healthy young subjects. It appears that the change in metformin pharmacokinetics with aging is primarily accounted for by a change in renal function (see Table 5). [See WARNINGS AND PRECAUTIONS and Use In Specific Populations].
Table 5: Select Mean (±S.D.) Metformin Pharmacokinetic
Parameters Following Single or Multiple Oral Doses of Metformin HCl
Immediate-Release Tablet
| Subject Groups: Metformin HCl a Immediate-Release Tablet dose (number of subjects) | Cmaxb (mcg/mL) | Tmaxc (hrs) | Renal Clearance (mL/min) |
| Healthy, nondiabetic adults: | |||
| 500 mg single dose (24) | 1.03 (± 0.33) | 2.75 (±0.81) | 600 (±132) |
| 850 mg single dose (74)d | 1.60 (±0.38) | 2.64 (±0.82) | 552 (±139) |
| 850 mg three times daily for 19 doses e (9) | 2.01 (±0.42) | 1.79 (±0.94) | 642 (±173) |
| Adults with type 2 diabetes mellitus: | |||
| 850 mg single dose (23) | 1.48 (±0.5) | 3.32 (±1.08) | 491 (±138) |
| 850 mg three times daily for 19 doses (9)e | 1.90 (±0.62) | 2.01 (±1.22) | 550 (±160) |
| f Elderly, healthy nondiabetic adults: | |||
| 850 mg single dose (12) | 2.45 (±0.70) | 2.71 (±1.05) | 412 (±98) |
| Renal-impaired adults: | |||
| 850 mg single dose Mild (CLcr g 61 to 90 mL/min) (5) | 1.86 (±0.52) | 3.20 (±0.45) | 384 (±122) |
| Moderate (CLcr 31 to 60 mL/min) (4) | 4.12 (±1.83) | 3.75 (±0.50) | 108 (±57) |
| Severe (CLcr 10 to 30 mL/min) (6) | 3.93 (±0.92) | 4.01 (±1.10) | 130 (±90) |
| a All doses given fasting except the first 18
doses of the multiple dose studies b Peak plasma concentration c Time to peak plasma concentration d Combined results (average means) of five studies: mean age 32 years (range 23 to 59 years) e Kinetic study done following dose 19, given fasting f Elderly subjects, mean age 71 years (range 65 to 81 years) g CLcr = creatinine clearance normalized to body surface area of 1.73 m² |
|||
Pharmacokinetics study has not been conducted on RIOMET ER in pediatric population. After administration of a single oral metformin hydrochloride 500 mg immediate-release tablet with food, geometric mean metformin Cmax and AUC differed less than 5% between pediatric type 2 diabetic patients (12 to 16 years of age) and gender- and weight-matched healthy adults (20 to 45 years of age), all with normal renal function.
Metformin pharmacokinetic parameters did not differ significantly between normal subjects and patients with type 2 diabetes mellitus when analyzed according to gender (males = 19, females = 16).
No studies of metformin pharmacokinetic parameters according to race have been performed.
Table 6: Effect of Coadministered Drug on Plasma
Metformin Systemic Exposure
| Coadministered Drug | Dose of Coadministered Drug* | Dose of Metformin* | Geometric Mean Ratio (ratio with/without coadministered drug) No Effect = 1.00 | ||
| AUC† | Cmax | ||||
| Glyburide | 5 mg | 850 mg | metformin | 0.91‡ | 0.93‡ |
| Furosemide | 40 mg | 850 mg | metformin | 1.09‡ | 1.22‡ |
| Nifedipine | 10 mg | 850 mg | metformin | 1.16 | 1.21 |
| Propranolol | 40 mg | 850 mg | metformin | 0.90 | 0.94 |
| Ibuprofen | 400 mg | 850 mg | metformin | 1.05‡ | 1.07‡ |
| Cationic drugs eliminated by renal tubular secretion may reduce metformin elimination [See WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS]. | |||||
| Cimetidine | 400 mg | 850 mg | metformin | 1.40 | 1.61 |
| Carbonic anhydrase inhibitors may cause metabolic acidosis [See WARNINGS AND PRECAUTIONS and DRUG INTERACTIONS]. | |||||
| Topiramate | 100 mg§ | 500 mg§ | metformin | 1.25§ | 1.17 |
| * All metformin and coadministered drugs were given as
single doses † AUC = AUC (INF) ‡Ratio of arithmetic means § At steady state with topiramate 100 mg every 12 hours and metformin 500 mg every 12 hours; AUC = AUC0-12h |
|||||
Table 7: Effect of Metformin on Coadministered Drug
Systemic Exposure
| Coadministered Drug | Dose of Coadministered Drug* | Dose of Metformin* | Geometric Mean Ratio (ratio with/without metformin) No Effect = 1.00 | ||
| AUC† | Cmax | ||||
| Glyburide | 5 mg | 850 mg | glyburide | 0.78‡ | 0.63‡ |
| Furosemide | 40 mg | 850 mg | furosemide | 0.87‡ | 0.69‡ |
| Nifedipine | 10 mg | 850 mg | nifedipine | 1.10§ | 1.08 |
| Propranolol | 40 mg | 850 mg | propranolol | 1.01§ | 1.02 |
| Ibuprofen | 400 mg | 850 mg | ibuprofen | 0.97¶ | 1.01¶ |
| Cimetidine | 400 mg | 850 mg | cimetidine | 0.95§ | 1.01 |
| * All metformin and coadministered drugs were given as
single doses † AUC = AUC (INF) unless otherwise noted ‡ Ratio of arithmetic means, p-value of difference <0.05 § AUC (0 - 24 hr) reported ¶ Ratio of arithmetic means |
|||||
A double-blind, placebo-controlled, multicenter US clinical trial involving obese patients with type 2 diabetes mellitus whose hyperglycemia was not adequately controlled with dietary management alone (baseline fasting plasma glucose [FPG] of approximately 240 mg/dL) was conducted. Patients were treated with metformin HCl immediate-release tablet (up to 2,550 mg/day) or placebo for 29 weeks. The results are presented in Table 8.
Table 8: Mean Change in Fasting Plasma Glucose and
HbA1c at Week 29 Comparing Metformin HCl vs Placebo in Patients with Type 2
Diabetes Mellitus
| Metformin HCl (n = 141) |
Placebo (n = 145) |
p-Value | |
| FPG (mg/dL | |||
| Baseline | 241.5 | 237.7 | NS* |
| Change at FINAL VISIT | -53.0 | 6.3 | 0.001 |
| Hemoglobin Aic (%) | |||
| Baseline | 8.4 | 8.2 | NS* |
| Change at FINAL VISIT | -1.4 | 0.4 | 0.001 |
| * Not statistically significant | |||
Mean baseline body weight was 201 lbs and 206 lbs in the metformin HCl and placebo arms, respectively. Mean change in body weight from baseline to week 29 was -1.4 lbs and -2.4 lbs in the metformin HCl and placebo arms, respectively. A 29-week, double-blind, placebo-controlled study of metformin HCl immediate-release tablet and glyburide, alone and in combination, was conducted in obese patients with type 2 diabetes mellitus who had failed to achieve adequate glycemic control while on maximum doses of glyburide (baseline FPG of approximately 250 mg/dL). Patients randomized to the combination arm started therapy with metformin HCl 500 mg immediate-release tablet and glyburide 20 mg. At the end of each week of the first 4 weeks of the trial, these patients had their dosages of metformin HCl immediate-release tablet increased by 500 mg if they had failed to reach target fasting plasma glucose. After week 4, such dosage adjustments were made monthly, although no patient was allowed to exceed metformin hydrochloride 2,500 mg immediate-release tablet. Patients in the metformin HCl immediate-release tablet only arm  (metformin plus placebo) discontinued glyburide and followed the same titration schedule. Patients in the glyburide arm continued the same dose of glyburide. At the end of the trial, approximately 70% of the patients in the combination group were taking metformin HCl immediate-release tablet 2,000 mg/glyburide 20 mg or metformin HCl immediate-release tablet 2,500 mg/glyburide 20 mg. The results are displayed in Table 9.
Table 9: Mean Change in Fasting Plasma Glucose and
HbA1c at Week 29 Comparing Metformin HCl/Glyburide (Comb) vs Glyburide (Glyb)
vs Metformin HCl (GLU): in Patients with Type 2 Diabetes Mellitus with
Inadequate Glycemic Control on Glyburide
| Comb (n = 213) |
Glyb (n = 209) |
GLU (n = 210) |
p-Values | |||
| Glyb vs Comb | GLU vs Comb | GLU vs Glyb | ||||
| Fasting Plasma Glucose (mg/dL) Baseline | 250.5 | 247.5 | 253.9 | NS* | NS* | NS* |
| Change at FINAL VISIT | -63.5 | 13.7 | -0.9 | 0.001 | 0.001 | 0.025 |
| Hemoglobin A1c (%) Baseline | 8.8 | 8.5 | 8.9 | NS* | NS* | 0.007 |
| Change at FINAL VISIT | -1.7 | 0.2 | -0.4 | 0.001 | 0.001 | 0.001 |
| * Not statistically significant | ||||||
Mean baseline body weight was 202 lbs, 203 lbs, and 204 lbs in the metformin HCl/glyburide, glyburide, and metformin HCl arms, respectively. Mean change in body weight from baseline to week 29 was 0.9 lbs, -0.7 lbs, and -8.4 lbs in the metformin HCl/glyburide, glyburide, and metformin HCl arms, respectively.
A double-blind, placebo-controlled study in pediatric patients aged 10 to 16 years with type 2 diabetes mellitus (mean FPG 182.2 mg/dL), treatment with metformin HCl immediate-release tablet (up to 2,000 mg/day) for up to 16 weeks (mean duration of treatment 11 weeks) was conducted. The results are displayed in Table 10.
Table 10: Mean Change in Fasting Plasma Glucose at
Week 16 Comparing metformin HCl vs Placebo in Pediatric Patientsa with Type 2
Diabetes Mellitus
| FPG (mg/dL) | Metformin HCl (n = 37) |
Placebo (n = 36) |
p-Value |
| Baseline | 162.4 | 192.3 | |
| Change at FINAL VISIT | -42.9 | 21.4 | <0.001 |
| a Pediatric patients mean age 13.8 years (range 10 to 16 years) | |||
Mean baseline body weight was 205 lbs and 189 lbs in the metformin HCl and placebo arms, respectively. Mean change in body weight from baseline to week 16 was -3.3 lbs and -2.0 lbs in the metformin and placebo arms, respectively.
A 24 week, double-blind, placebo-controlled study of metformin HCl extended-release tablet, taken once daily with the evening meal, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise. Patients entering the study had a mean baseline HbA1c of 8% and a mean baseline FPG of 176 mg/dL. The treatment dose was increased to 1,500 mg once daily if at week 12 HbA1c was ≥ 7% but < 8% (patients with HbA1c ≥ 8% were discontinued from the study). At the final visit (24-week), mean HbA1c had increased 0.2% from baseline in placebo patients and decreased 0.6% with metformin HCl extended-release tablet.
A 16-week, double-blind, placebo-controlled, dose-response study of metformin HCl extendedrelease tablet, taken once daily with the evening meal or twice daily with meals, was conducted in patients with type 2 diabetes who had failed to achieve glycemic control with diet and exercise. The results are shown in Table 11.
Table 11: Mean Changes from Baseline* in HbA1c and
Fasting Plasma Glucose at Week 16 Comparing Metformin HCl Extended-Release
Tablets vs Placebo in Patients with Type 2 Diabetes Mellitus
| Metformin HCl Extended-Release Tablets | Placebo | |||||
| 500 mg Once Daily | 1,000 mg Once Daily | 1,500 mg Once Daily | 2,000 mg Once Daily | 1,000 mg Twice Daily | ||
| Hemoglobin A1c (%) | (n = 115) | (n = 115) | (n = 111) | (n = 125) | (n = 112) | (n = 111) |
| Baseline | 8.2 | 8.4 | 8.3 | 8.4 | 8.4 | 8.4 |
| Change at FINAL VISIT | -0.4 | -0.6 | -0.9 | -0.8 | -1.1 | 0.1 |
| p-valuea | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | -- |
| FPG (mg/dL) | (n = 126) | (n = 118) | (n = 120) | (n = 132) | (n = 122) | (n = 113) |
| Baseline | 182.7 | 183.7 | 178.9 | 181.0 | 181.6 | 179.6 |
| Change at FINAL VISIT | -15.2 | -19.3 | -28.5 | -29.9 | -33.6 | 7.6 |
| p-valuea | < 0.001 | < 0.001 | < 0.001 | < 0.001 | < 0.001 | -- |
| a All comparisons versus Placebo | ||||||
Mean baseline body weight was 193 lbs, 192 lbs, 188 lbs, 196 lbs, 193 lbs and 194 lbs in the metformin HCl extended-release tablet 500 mg , 1,000 mg, 1,500 mg, and 2,000 mg once daily, 1,000 mg twice daily and placebo arms, respectively. Mean change in body weight from baseline to week 16 was -1.3 lbs, -1.3 lbs, -0.7 lbs, -1.5 lbs, -2.2 lbs and -1.8 lbs, respectively.
A 24 week, double-blind, randomized study of metformin HCl extended-release tablet, taken once daily with the evening meal, and metformin HCl immediate-release tablet, taken twice daily (with breakfast and evening meal), was conducted in patients with type 2 diabetes mellitus who had been treated with metformin HCl 500 mg immediate-release tablets twice daily for at least 8 weeks prior to study entry. The results are shown in Table 12.
Table 12: Mean Changes from Baseline* in HbA1c and
Fasting Plasma Glucose at Week 24 Comparing Metformin HCl Extended-Release
Tablet vs Metformin HCl Immediate-Release Tablet in Patients with Type 2 Diabetes
Mellitus
| Metformin HCl Immediate-Release Tablet 500 mg Twice Daily | Metformin HCl Extended-Release Tablet | ||
| 1,000 mg Once Daily | 1,500 mg Once Daily | ||
| Hemoglobin A1c (%) | (n = 67) | (n = 72) | (n = 66) |
| Baseline | 7.06 | 6.99 | 7.02 |
| Change at FINAL VISIT | 0.14a | 0.27 | 0.13 |
| (95% CI) | (-0.04, 0.31) | (0.11, 0.43) | (-0.02, 0.28) |
| FPG (mg/dL) | (n = 69) | n N 7 ) | (n = 70) |
| Baseline | 127.2 | 131.0 | 131.4 |
| Change at FINAL VISIT | 14.0 | 11.5 | 7.6 |
| (95% CI) | (7.0, 21.0) | (4.4, 18.6) | (1.0, 14.2) |
| *a n = 68 | |||
Mean baseline body weight was 210lbs, 203 lbs and 193 lbs in the metformin HCl immediate-release tablet 500 mg twice daily, and metformin HCl extended-release tablet 1,000 mg and 1,500 mg once daily arms, respectively. Mean change in body weight from baseline to week 24 was 0.9 lbs, 1.1 lbs and 0.9 lbs, respectively.
